KR20220035137A

KR20220035137A - Ppm1a 억제제 및 그의 사용 방법

Ppm1a 억제제 및 그의 사용 방법 Download PDF

Info

Publication number: KR20220035137A
Authority: KR; South Korea
Prior art keywords: ppm1a; oligonucleotide; seq; patient; disease
Prior art date: 2019-06-21
Legal status : Withdrawn

Application number

KR1020227002134A

Other languages

English (en)

Korean (ko)

Inventor

샌드라 힝클리

던컨 브라운

수드히르 아그라왈

다니엘 엘바움

Original Assignee

큐랄리스 코포레이션

Priority date

2019-06-21

Filing date

2020-06-19

Publication date

2022-03-21

2020-06-19 Application filed by 큐랄리스 코포레이션 filed Critical 큐랄리스 코포레이션

2022-03-21 Publication of KR20220035137A publication Critical patent/KR20220035137A/ko

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 141
239000003112 inhibitor Substances 0.000 title claims abstract description 72
102100022343 Protein phosphatase 1A Human genes 0.000 title claims abstract description 46
101000620650 Homo sapiens Protein phosphatase 1A Proteins 0.000 title claims abstract description 37
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 565
239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 407
238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 407
208000012902 Nervous system disease Diseases 0.000 claims abstract description 142
208000025966 Neurological disease Diseases 0.000 claims abstract description 138
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 130
201000011240 Frontotemporal dementia Diseases 0.000 claims abstract description 88
230000000694 effects Effects 0.000 claims abstract description 83
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 70
239000003814 drug Substances 0.000 claims abstract description 59
230000014509 gene expression Effects 0.000 claims abstract description 35
102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims abstract description 31
101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims abstract description 7
239000002777 nucleoside Substances 0.000 claims description 286
239000002773 nucleotide Substances 0.000 claims description 215
125000003729 nucleotide group Chemical group 0.000 claims description 215
125000003835 nucleoside group Chemical group 0.000 claims description 186
150000003839 salts Chemical class 0.000 claims description 175
235000000346 sugar Nutrition 0.000 claims description 132
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 119
-1 alkyl phosphate Chemical compound 0.000 claims description 116
201000001119 neuropathy Diseases 0.000 claims description 100
230000007823 neuropathy Effects 0.000 claims description 100
208000033808 peripheral neuropathy Diseases 0.000 claims description 100
150000003833 nucleoside derivatives Chemical class 0.000 claims description 99
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 91
102000039446 nucleic acids Human genes 0.000 claims description 74
108020004707 nucleic acids Proteins 0.000 claims description 74
238000011282 treatment Methods 0.000 claims description 71
230000000295 complement effect Effects 0.000 claims description 63
150000007523 nucleic acids Chemical class 0.000 claims description 56
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
150000004713 phosphodiesters Chemical class 0.000 claims description 49
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 46
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 46
210000004027 cell Anatomy 0.000 claims description 44
201000010099 disease Diseases 0.000 claims description 43
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 40
201000008319 inclusion body myositis Diseases 0.000 claims description 40
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 40
229940124597 therapeutic agent Drugs 0.000 claims description 40
150000001875 compounds Chemical class 0.000 claims description 39
208000024827 Alzheimer disease Diseases 0.000 claims description 38
208000018737 Parkinson disease Diseases 0.000 claims description 38
108090000623 proteins and genes Proteins 0.000 claims description 36
208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 33
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 30
101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 claims description 27
102100024007 Neurofilament heavy polypeptide Human genes 0.000 claims description 27
230000007850 degeneration Effects 0.000 claims description 22
108091093037 Peptide nucleic acid Proteins 0.000 claims description 21
206010008025 Cerebellar ataxia Diseases 0.000 claims description 20
201000008892 GM1 Gangliosidosis Diseases 0.000 claims description 20
208000015872 Gaucher disease Diseases 0.000 claims description 20
241000282414 Homo sapiens Species 0.000 claims description 20
208000023105 Huntington disease Diseases 0.000 claims description 20
208000030886 Traumatic Brain injury Diseases 0.000 claims description 20
238000002512 chemotherapy Methods 0.000 claims description 20
230000001054 cortical effect Effects 0.000 claims description 20
239000005549 deoxyribonucleoside Substances 0.000 claims description 20
208000020431 spinal cord injury Diseases 0.000 claims description 20
208000008955 Mucolipidoses Diseases 0.000 claims description 19
NFFPKRVXIPSSQR-BXXZVTAOSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanamide Chemical compound NC(=O)[C@H](O)[C@H](O)[C@H](O)CO NFFPKRVXIPSSQR-BXXZVTAOSA-N 0.000 claims description 18
206010006074 Brachial plexus injury Diseases 0.000 claims description 18
229910019142 PO4 Inorganic materials 0.000 claims description 18
206010037549 Purpura Diseases 0.000 claims description 18
241001672981 Purpura Species 0.000 claims description 18
208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims description 18
208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 17
239000010452 phosphate Substances 0.000 claims description 17
125000002619 bicyclic group Chemical group 0.000 claims description 16
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 15
230000004048 modification Effects 0.000 claims description 14
238000012986 modification Methods 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 14
238000000554 physical therapy Methods 0.000 claims description 14
239000002215 arabinonucleoside Substances 0.000 claims description 13
229940104302 cytosine Drugs 0.000 claims description 13
238000001584 occupational therapy Methods 0.000 claims description 13
101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 claims description 12
102100023057 Neurofilament light polypeptide Human genes 0.000 claims description 12
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 12
238000002560 therapeutic procedure Methods 0.000 claims description 12
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
230000035772 mutation Effects 0.000 claims description 11
239000002342 ribonucleoside Substances 0.000 claims description 11
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
208000010886 Peripheral nerve injury Diseases 0.000 claims description 10
LKJCZXIGFPOQPC-UHFFFAOYSA-N SSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSS LKJCZXIGFPOQPC-UHFFFAOYSA-N 0.000 claims description 10
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 10
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 10
230000000638 stimulation Effects 0.000 claims description 10
108700030955 C9orf72 Proteins 0.000 claims description 9
102100023677 Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Human genes 0.000 claims description 9
101000907013 Homo sapiens Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Proteins 0.000 claims description 9
125000005600 alkyl phosphonate group Chemical group 0.000 claims description 9
210000004556 brain Anatomy 0.000 claims description 9
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 9
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims description 9
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 9
101150014718 C9orf72 gene Proteins 0.000 claims description 8
QVEBFCHKJKCIDF-UHFFFAOYSA-N COCCCOP(O)=O Chemical compound COCCCOP(O)=O QVEBFCHKJKCIDF-UHFFFAOYSA-N 0.000 claims description 8
208000028389 Nerve injury Diseases 0.000 claims description 8
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 8
102100020814 Sequestosome-1 Human genes 0.000 claims description 8
ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 8
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 claims description 8
230000008764 nerve damage Effects 0.000 claims description 8
210000000578 peripheral nerve Anatomy 0.000 claims description 8
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
230000000699 topical effect Effects 0.000 claims description 8
ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 7
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 7
101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 claims description 7
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
101710105644 Protein phosphatase 1A Proteins 0.000 claims description 7
229930185560 Pseudouridine Natural products 0.000 claims description 7
PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 7
101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 7
WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 7
210000004369 blood Anatomy 0.000 claims description 7
239000008280 blood Substances 0.000 claims description 7
235000017471 coenzyme Q10 Nutrition 0.000 claims description 7
229940110767 coenzyme Q10 Drugs 0.000 claims description 7
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 7
229910052744 lithium Inorganic materials 0.000 claims description 7
PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 7
238000002630 speech therapy Methods 0.000 claims description 7
230000004083 survival effect Effects 0.000 claims description 7
210000001519 tissue Anatomy 0.000 claims description 7
YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 6
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 6
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 6
239000001961 anticonvulsive agent Substances 0.000 claims description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
229960002866 duloxetine Drugs 0.000 claims description 6
210000001808 exosome Anatomy 0.000 claims description 6
210000003608 fece Anatomy 0.000 claims description 6
230000006870 function Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
238000007913 intrathecal administration Methods 0.000 claims description 6
210000002751 lymph Anatomy 0.000 claims description 6
230000026731 phosphorylation Effects 0.000 claims description 6
238000006366 phosphorylation reaction Methods 0.000 claims description 6
229960003089 pramipexole Drugs 0.000 claims description 6
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 6
229960004136 rivastigmine Drugs 0.000 claims description 6
229960001879 ropinirole Drugs 0.000 claims description 6
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 6
229960003179 rotigotine Drugs 0.000 claims description 6
KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 6
FDTAUJJRHBRHIJ-FDJAAIFISA-N tpi-287 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@H](OC(C)=O)[C@@H]3OC(O[C@H]4C[C@H]5OC[C@]5([C@@H]1[C@]34C)OC(C)=O)C=C)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 FDTAUJJRHBRHIJ-FDJAAIFISA-N 0.000 claims description 6
210000002700 urine Anatomy 0.000 claims description 6
101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 claims description 5
YBZSGIWIPOUSHY-UHFFFAOYSA-N troriluzole Chemical compound NCC(=O)NCC(N(CC(NC=1SC2=C(N=1)C=CC(=C2)OC(F)(F)F)=O)C)=O YBZSGIWIPOUSHY-UHFFFAOYSA-N 0.000 claims description 5
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
JDXCOXKBIGBZSK-PSNKNOTQSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1c[nH]c2ncccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(O)=O)C(O)=O JDXCOXKBIGBZSK-PSNKNOTQSA-N 0.000 claims description 4
BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 claims description 4
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
ZPPUMAMZIMPJGP-UHFFFAOYSA-N 2-methyl-2-[3-methyl-4-[[4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]pyrazol-1-yl]propanenitrile Chemical compound C1=C(C(F)(F)F)C(NC)=NC(NC=2C(=NN(C=2)C(C)(C)C#N)C)=N1 ZPPUMAMZIMPJGP-UHFFFAOYSA-N 0.000 claims description 4
JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 claims description 4
IHLOTZVBEUFDMD-UUOKFMHZSA-N 7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,2-dioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 IHLOTZVBEUFDMD-UUOKFMHZSA-N 0.000 claims description 4
102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
229940076606 Casein kinase 1 inhibitor Drugs 0.000 claims description 4
229940126630 DNL201 Drugs 0.000 claims description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
108010093031 Galactosidases Proteins 0.000 claims description 4
102000002464 Galactosidases Human genes 0.000 claims description 4
239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 4
229940124786 LRRK2 inhibitor Drugs 0.000 claims description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
ZBQPJUMVWHDCRQ-UHFFFAOYSA-N SSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSS ZBQPJUMVWHDCRQ-UHFFFAOYSA-N 0.000 claims description 4
SPUUKOIOZNVGHK-UHFFFAOYSA-N SSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSS SPUUKOIOZNVGHK-UHFFFAOYSA-N 0.000 claims description 4
HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 4
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 4
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
229960003805 amantadine Drugs 0.000 claims description 4
230000001773 anti-convulsant effect Effects 0.000 claims description 4
229960003965 antiepileptics Drugs 0.000 claims description 4
229960004046 apomorphine Drugs 0.000 claims description 4
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 4
229940049706 benzodiazepine Drugs 0.000 claims description 4
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 4
210000000133 brain stem Anatomy 0.000 claims description 4
229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
238000009223 counseling Methods 0.000 claims description 4
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
229960003530 donepezil Drugs 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 4
229960003337 entacapone Drugs 0.000 claims description 4
229960003980 galantamine Drugs 0.000 claims description 4
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
238000001415 gene therapy Methods 0.000 claims description 4
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
229960004427 isradipine Drugs 0.000 claims description 4
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 4
229960001848 lamotrigine Drugs 0.000 claims description 4
229960004640 memantine Drugs 0.000 claims description 4
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 4
GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims description 4
229960002967 nabilone Drugs 0.000 claims description 4
229960002715 nicotine Drugs 0.000 claims description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
229960003512 nicotinic acid Drugs 0.000 claims description 4
235000001968 nicotinic acid Nutrition 0.000 claims description 4
239000011664 nicotinic acid Substances 0.000 claims description 4
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 4
229960001346 nilotinib Drugs 0.000 claims description 4
230000000399 orthopedic effect Effects 0.000 claims description 4
229960005095 pioglitazone Drugs 0.000 claims description 4
DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 claims description 4
229950008939 preladenant Drugs 0.000 claims description 4
YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 4
229950003764 pridopidine Drugs 0.000 claims description 4
230000002685 pulmonary effect Effects 0.000 claims description 4
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 4
229960000245 rasagiline Drugs 0.000 claims description 4
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 4
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 4
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 4
229960003946 selegiline Drugs 0.000 claims description 4
238000011476 stem cell transplantation Methods 0.000 claims description 4
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims description 4
229960004603 tolcapone Drugs 0.000 claims description 4
229960001032 trihexyphenidyl Drugs 0.000 claims description 4
229940121629 troriluzole Drugs 0.000 claims description 4
229960000317 yohimbine Drugs 0.000 claims description 4
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 4
229960002911 zonisamide Drugs 0.000 claims description 4
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 3
WDZRUXKVLXELHY-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSS WDZRUXKVLXELHY-UHFFFAOYSA-N 0.000 claims description 3
VDTZYABQBPMANF-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSSS VDTZYABQBPMANF-UHFFFAOYSA-N 0.000 claims description 3
235000012000 cholesterol Nutrition 0.000 claims description 3
108010072166 idursulfase Proteins 0.000 claims description 3
229960004502 levodopa Drugs 0.000 claims description 3
210000000653 nervous system Anatomy 0.000 claims description 3
235000016709 nutrition Nutrition 0.000 claims description 3
230000009467 reduction Effects 0.000 claims description 3
229960004181 riluzole Drugs 0.000 claims description 3
239000000758 substrate Substances 0.000 claims description 3
229940095064 tartrate Drugs 0.000 claims description 3
AKQXQLUNFKDZBN-UHFFFAOYSA-N tavapadon Chemical compound C=1C=C(C=2N(C(=O)NC(=O)C=2C)C)C(C)=CC=1OC1=NC=CC=C1C(F)(F)F AKQXQLUNFKDZBN-UHFFFAOYSA-N 0.000 claims description 3
230000001755 vocal effect Effects 0.000 claims description 3
NJWCVQBHNBLNOZ-ZRMYETLXSA-N (1S,3R,5R,6S,8R,10R,11S,13S,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,47R,48S,49R)-5,20,30,35-tetrakis(hydroxymethyl)-49-(2-hydroxypropoxy)-10,15,25-tris(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,47,48-dodecol Chemical compound CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1C[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](OCC(C)O)[C@H]3O NJWCVQBHNBLNOZ-ZRMYETLXSA-N 0.000 claims description 2
PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 claims description 2
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims description 2
VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 claims description 2
MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 2
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 2
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N (3e)-n-[(2r)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C([C@H](O)CN1CCCCC1)O\N=C(\Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-ZPTIMJQQSA-N 0.000 claims description 2
BVBRUQYHUXKZMQ-JNVAYQLDSA-N (3s,8s,9s,10r,13r,14s,17r)-3,10,13-trimethyl-17-[(2r,5s)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@](C)(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CC[C@](C)(O)C(F)(F)F)C)[C@@]1(C)CC2 BVBRUQYHUXKZMQ-JNVAYQLDSA-N 0.000 claims description 2
YFRBKEVUUCQYOW-UHFFFAOYSA-N 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=N1)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 YFRBKEVUUCQYOW-UHFFFAOYSA-N 0.000 claims description 2
JSAQBOQCZJHWMA-XMMPIXPASA-N 1-tert-butyl-N-[(5R)-8-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-2-(oxetan-3-yl)-1,3,4,5-tetrahydro-2-benzazepin-5-yl]triazole-4-carboxamide Chemical compound C(C)(C)(C)N1N=NC(=C1)C(=O)N[C@H]1C2=C(CN(CC1)C1COC1)C=C(C=C2)C1=NC(=NC=C1)NC=1C=NN(C=1)C JSAQBOQCZJHWMA-XMMPIXPASA-N 0.000 claims description 2
LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 2
FUZYTVDVLBBXDL-UHFFFAOYSA-N 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide Chemical compound N1C2=CC=C(Cl)C=C2C2=C1C(C(=O)N)CCC2 FUZYTVDVLBBXDL-UHFFFAOYSA-N 0.000 claims description 2
102000014461 Ataxins Human genes 0.000 claims description 2
108010078286 Ataxins Proteins 0.000 claims description 2
229940125889 BIIB091 Drugs 0.000 claims description 2
229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 2
MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 2
102000003951 Erythropoietin Human genes 0.000 claims description 2
108090000394 Erythropoietin Proteins 0.000 claims description 2
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 2
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 2
101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
229940125966 JNJ-54861911 Drugs 0.000 claims description 2
108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims description 2
108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims description 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 2
JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 2
102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims description 2
102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 claims description 2
102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
229940126644 SAGE-718 Drugs 0.000 claims description 2
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 2
QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 2
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 claims description 2
229960004308 acetylcysteine Drugs 0.000 claims description 2
229960005339 acitretin Drugs 0.000 claims description 2
229960002964 adalimumab Drugs 0.000 claims description 2
238000011374 additional therapy Methods 0.000 claims description 2
229950008995 aducanumab Drugs 0.000 claims description 2
MMLDHJRGTZHNHV-BPGUCPLFSA-N alicapistat Chemical compound O=C([C@@H]1N(C(=O)CC1)CC=1C=CC=CC=1)NC(C(=O)C(=O)NC1CC1)CC1=CC=CC=C1 MMLDHJRGTZHNHV-BPGUCPLFSA-N 0.000 claims description 2
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 2
230000000735 allogeneic effect Effects 0.000 claims description 2
230000000049 anti-anxiety effect Effects 0.000 claims description 2
230000001430 anti-depressive effect Effects 0.000 claims description 2
230000000561 anti-psychotic effect Effects 0.000 claims description 2
230000000573 anti-seizure effect Effects 0.000 claims description 2
229940125713 antianxiety drug Drugs 0.000 claims description 2
239000003146 anticoagulant agent Substances 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
229940125681 anticonvulsant agent Drugs 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
239000002249 anxiolytic agent Substances 0.000 claims description 2
229940039856 aricept Drugs 0.000 claims description 2
229950011582 arimoclomol Drugs 0.000 claims description 2
239000000607 artificial tear Substances 0.000 claims description 2
VLLFGVHGKLDDLW-SFHVURJKSA-N atabecestat Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C=CSC(N)=N1 VLLFGVHGKLDDLW-SFHVURJKSA-N 0.000 claims description 2
230000004900 autophagic degradation Effects 0.000 claims description 2
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
229960002170 azathioprine Drugs 0.000 claims description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
JUTBAVRYDAKVGQ-UHFFFAOYSA-N bdth2 Chemical compound SCCNC(=O)C1=CC=CC(C(=O)NCCS)=C1 JUTBAVRYDAKVGQ-UHFFFAOYSA-N 0.000 claims description 2
229950003210 bradanicline Drugs 0.000 claims description 2
OXKRFEWMSWPKKV-RXVVDRJESA-N bradanicline Chemical compound C([C@@H]1N2CCC(CC2)[C@@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-RXVVDRJESA-N 0.000 claims description 2
QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 2
229950011318 cannabidiol Drugs 0.000 claims description 2
ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 2
229960000623 carbamazepine Drugs 0.000 claims description 2
229940057922 carbatrol Drugs 0.000 claims description 2
229940047495 celebrex Drugs 0.000 claims description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
229940049197 cerezyme Drugs 0.000 claims description 2
SXMBKHYDZOCBMT-PPUGGXLSSA-N chembl2151197 Chemical compound C1[C@@H](C(=O)NCC)C[C@@]1(F)C(C=C1F)=CC=C1CN1CCCC1 SXMBKHYDZOCBMT-PPUGGXLSSA-N 0.000 claims description 2
229960001076 chlorpromazine Drugs 0.000 claims description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
229960003405 ciprofloxacin Drugs 0.000 claims description 2
229960003120 clonazepam Drugs 0.000 claims description 2
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 2
229960001338 colchicine Drugs 0.000 claims description 2
201000008692 congenital stationary night blindness 1A Diseases 0.000 claims description 2
239000003246 corticosteroid Substances 0.000 claims description 2
229960003624 creatine Drugs 0.000 claims description 2
239000006046 creatine Substances 0.000 claims description 2
229960003834 dapagliflozin Drugs 0.000 claims description 2
229960000860 dapsone Drugs 0.000 claims description 2
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
229960001985 dextromethorphan Drugs 0.000 claims description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 2
229960003529 diazepam Drugs 0.000 claims description 2
PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 2
229940052760 dopamine agonists Drugs 0.000 claims description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
230000009977 dual effect Effects 0.000 claims description 2
QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims description 2
229950009041 edaravone Drugs 0.000 claims description 2
229940012882 elaprase Drugs 0.000 claims description 2
230000002255 enzymatic effect Effects 0.000 claims description 2
229940105423 erythropoietin Drugs 0.000 claims description 2
WRUIDZKNUAHKTR-UHFFFAOYSA-N ethyl 5-(benzylamino)-6-(cyclohexylamino)pyridine-3-carboxylate Chemical compound C=1C=CC=CC=1CNC1=CC(C(=O)OCC)=CN=C1NC1CCCCC1 WRUIDZKNUAHKTR-UHFFFAOYSA-N 0.000 claims description 2
229940108366 exelon Drugs 0.000 claims description 2
229960002297 fenofibrate Drugs 0.000 claims description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
229960002870 gabapentin Drugs 0.000 claims description 2
230000002068 genetic effect Effects 0.000 claims description 2
229960003878 haloperidol Drugs 0.000 claims description 2
239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 2
108010039650 imiglucerase Proteins 0.000 claims description 2
208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
230000001861 immunosuppressant effect Effects 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 2
235000019136 lipoic acid Nutrition 0.000 claims description 2
229960001078 lithium Drugs 0.000 claims description 2
238000009136 lithium therapy Methods 0.000 claims description 2
238000007726 management method Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000002483 medication Methods 0.000 claims description 2
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims description 2
229960004616 medroxyprogesterone Drugs 0.000 claims description 2
DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 2
229960004023 minocycline Drugs 0.000 claims description 2
239000003158 myorelaxant agent Substances 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
239000002581 neurotoxin Substances 0.000 claims description 2
231100000618 neurotoxin Toxicity 0.000 claims description 2
235000020956 nicotinamide riboside Nutrition 0.000 claims description 2
239000011618 nicotinamide riboside Substances 0.000 claims description 2
229960005017 olanzapine Drugs 0.000 claims description 2
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
229940005483 opioid analgesics Drugs 0.000 claims description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
239000003368 psychostimulant agent Substances 0.000 claims description 2
229960004431 quetiapine Drugs 0.000 claims description 2
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 2
229940051845 razadyne Drugs 0.000 claims description 2
238000009252 recreational therapy Methods 0.000 claims description 2
238000009256 replacement therapy Methods 0.000 claims description 2
230000000241 respiratory effect Effects 0.000 claims description 2
235000021283 resveratrol Nutrition 0.000 claims description 2
229940016667 resveratrol Drugs 0.000 claims description 2
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
229960001534 risperidone Drugs 0.000 claims description 2
239000003751 serotonin 6 antagonist Substances 0.000 claims description 2
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 2
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
238000009168 stem cell therapy Methods 0.000 claims description 2
238000009580 stem-cell therapy Methods 0.000 claims description 2
239000000021 stimulant Substances 0.000 claims description 2
238000011477 surgical intervention Methods 0.000 claims description 2
229960005333 tetrabenazine Drugs 0.000 claims description 2
229960002663 thioctic acid Drugs 0.000 claims description 2
PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 claims description 2
229950005284 tideglusib Drugs 0.000 claims description 2
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 2
229960002905 tolfenamic acid Drugs 0.000 claims description 2
238000007483 tonsillectomy Methods 0.000 claims description 2
238000011491 transcranial magnetic stimulation Methods 0.000 claims description 2
238000012546 transfer Methods 0.000 claims description 2
239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 2
229960001661 ursodiol Drugs 0.000 claims description 2
229940102566 valproate Drugs 0.000 claims description 2
229940121352 zilucoplan Drugs 0.000 claims description 2
229960001475 zolpidem Drugs 0.000 claims description 2
ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 2
208000024839 Mucopolysaccharidosis type 2, severe form Diseases 0.000 claims 6
208000033541 severe form mucopolysaccharidosis type 2 Diseases 0.000 claims 6
208000014060 Niemann-Pick disease Diseases 0.000 claims 5
102000043334 C9orf72 Human genes 0.000 claims 2
101710137943 Complement control protein C3 Proteins 0.000 claims 2
102000003890 RNA-binding protein FUS Human genes 0.000 claims 2
108090000292 RNA-binding protein FUS Proteins 0.000 claims 2
102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims 2
101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims 2
JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 claims 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 2
201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
102100029199 Iduronate 2-sulfatase Human genes 0.000 claims 1
208000031814 IgA Vasculitis Diseases 0.000 claims 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
WXNXCEHXYPACJF-ZETCQYMHSA-M N-acetyl-L-leucinate Chemical compound CC(C)C[C@@H](C([O-])=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-M 0.000 claims 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
239000002671 adjuvant Substances 0.000 claims 1
229960004580 glibenclamide Drugs 0.000 claims 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
229960002396 idursulfase Drugs 0.000 claims 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
229940035363 muscle relaxants Drugs 0.000 claims 1
150000008299 phosphorodiamidates Chemical class 0.000 claims 1
238000001356 surgical procedure Methods 0.000 claims 1
239000004474 valine Substances 0.000 claims 1
229960004295 valine Drugs 0.000 claims 1
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 40
230000002829 reductive effect Effects 0.000 abstract description 5
238000002360 preparation method Methods 0.000 abstract description 4
108020004999 messenger RNA Proteins 0.000 description 103
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 96
101150003711 PPM1A gene Proteins 0.000 description 89
238000003197 gene knockdown Methods 0.000 description 58
239000000047 product Substances 0.000 description 51
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 49
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 48
229940104230 thymidine Drugs 0.000 description 48
PUDXUJRJLRLJIU-QYVSTXNMSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-ol Chemical group COCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PUDXUJRJLRLJIU-QYVSTXNMSA-N 0.000 description 47
DLLBJSLIKOKFHE-WOUKDFQISA-N 2-amino-9-[(2r,3r,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-3h-purin-6-one Chemical group COCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 DLLBJSLIKOKFHE-WOUKDFQISA-N 0.000 description 47
108020004414 DNA Proteins 0.000 description 45
102000053602 DNA Human genes 0.000 description 45
239000000203 mixture Substances 0.000 description 36
230000000692 anti-sense effect Effects 0.000 description 28
230000000875 corresponding effect Effects 0.000 description 26
101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 24
208000005264 motor neuron disease Diseases 0.000 description 22
125000000217 alkyl group Chemical group 0.000 description 20
229920002477 rna polymer Polymers 0.000 description 20
208000024891 symptom Diseases 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 16
239000004055 small Interfering RNA Substances 0.000 description 16
208000010577 Niemann-Pick disease type C Diseases 0.000 description 15
210000002161 motor neuron Anatomy 0.000 description 15
108020005004 Guide RNA Proteins 0.000 description 14
239000002585 base Substances 0.000 description 14
229910052799 carbon Inorganic materials 0.000 description 14
108010029485 Protein Isoforms Proteins 0.000 description 13
102000001708 Protein Isoforms Human genes 0.000 description 13
125000003118 aryl group Chemical group 0.000 description 13
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 13
208000026072 Motor neurone disease Diseases 0.000 description 12
150000008163 sugars Chemical class 0.000 description 12
125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 10
125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 10
108020004459 Small interfering RNA Proteins 0.000 description 10
125000002252 acyl group Chemical group 0.000 description 10
208000035475 disorder Diseases 0.000 description 10
229910052739 hydrogen Inorganic materials 0.000 description 10
125000006239 protecting group Chemical group 0.000 description 10
108091027967 Small hairpin RNA Proteins 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
108091026890 Coding region Proteins 0.000 description 8
101710163270 Nuclease Proteins 0.000 description 8
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 7
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
102000018709 Valosin Containing Protein Human genes 0.000 description 6
108010027273 Valosin Containing Protein Proteins 0.000 description 6
108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
229910052731 fluorine Inorganic materials 0.000 description 6
125000001072 heteroaryl group Chemical class 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
230000000750 progressive effect Effects 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
125000001424 substituent group Chemical group 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
238000001890 transfection Methods 0.000 description 6
108091033409 CRISPR Proteins 0.000 description 5
101100464886 Mus musculus Ppm1a gene Proteins 0.000 description 5
208000007101 Muscle Cramp Diseases 0.000 description 5
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
238000007385 chemical modification Methods 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
150000002243 furanoses Chemical group 0.000 description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
230000000926 neurological effect Effects 0.000 description 5
230000037361 pathway Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000008685 targeting Effects 0.000 description 5
239000012096 transfection reagent Substances 0.000 description 5
UFLDDSWIGVXVPQ-UHFFFAOYSA-N 2-amino-5-methyl-2,9-dihydro-1h-purin-6-one Chemical compound N1=CNC2(C)C1=NC(N)NC2=O UFLDDSWIGVXVPQ-UHFFFAOYSA-N 0.000 description 4
229930024421 Adenine Natural products 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
102100022987 Angiogenin Human genes 0.000 description 4
108010032951 Ataxin2 Proteins 0.000 description 4
102000007370 Ataxin2 Human genes 0.000 description 4
238000010354 CRISPR gene editing Methods 0.000 description 4
239000005977 Ethylene Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
206010033799 Paralysis Diseases 0.000 description 4
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 4
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 4
208000005392 Spasm Diseases 0.000 description 4
102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 4
108091023045 Untranslated Region Proteins 0.000 description 4
229960000643 adenine Drugs 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
125000004103 aminoalkyl group Chemical group 0.000 description 4
108010072788 angiogenin Proteins 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
230000005782 double-strand break Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
125000004430 oxygen atom Chemical group O* 0.000 description 4
208000021090 palsy Diseases 0.000 description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
239000002904 solvent Substances 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
229940113082 thymine Drugs 0.000 description 4
229940035893 uracil Drugs 0.000 description 4
238000001262 western blot Methods 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
108020005345 3' Untranslated Regions Proteins 0.000 description 3
108020003589 5' Untranslated Regions Proteins 0.000 description 3
YQAHIPFUPOMGRC-UHFFFAOYSA-N 5-methylpurine Chemical compound C1=NC=NC2=NC=NC21C YQAHIPFUPOMGRC-UHFFFAOYSA-N 0.000 description 3
TWGNOYAGHYUFFR-UHFFFAOYSA-N 5-methylpyrimidine Chemical compound CC1=CN=CN=C1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 3
206010013887 Dysarthria Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
206010064571 Gene mutation Diseases 0.000 description 3
101001139062 Homo sapiens Kinesin heavy chain isoform 5A Proteins 0.000 description 3
101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 description 3
102100020685 Kinesin heavy chain isoform 5A Human genes 0.000 description 3
102100038645 Matrin-3 Human genes 0.000 description 3
101710146614 Matrin-3 Proteins 0.000 description 3
206010028289 Muscle atrophy Diseases 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
102100027178 Probable helicase senataxin Human genes 0.000 description 3
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 3
102100039933 Ubiquilin-2 Human genes 0.000 description 3
101710173440 Ubiquilin-2 Proteins 0.000 description 3
102100032026 Vesicle-associated membrane protein-associated protein B/C Human genes 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
230000037444 atrophy Effects 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
201000010901 lateral sclerosis Diseases 0.000 description 3
201000000585 muscular atrophy Diseases 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008439 repair process Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
125000004962 sulfoxyl group Chemical group 0.000 description 3
230000009747 swallowing Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
230000014616 translation Effects 0.000 description 3
SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 2
RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 description 2
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
102100032047 Alsin Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102100024297 Cilia- and flagella-associated protein 410 Human genes 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
208000019505 Deglutition disease Diseases 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
101000980066 Homo sapiens Cilia- and flagella-associated protein 410 Proteins 0.000 description 2
101000987578 Homo sapiens Peripherin Proteins 0.000 description 2
101000577619 Homo sapiens Profilin-1 Proteins 0.000 description 2
101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 2
101000775932 Homo sapiens Vesicle-associated membrane protein-associated protein B/C Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000010428 Muscle Weakness Diseases 0.000 description 2
206010028372 Muscular weakness Diseases 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102100028465 Peripherin Human genes 0.000 description 2
206010034719 Personality change Diseases 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 2
208000032319 Primary lateral sclerosis Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
102100028857 Profilin-1 Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
RRTCJVBFMMTZSS-UHFFFAOYSA-N SSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSS RRTCJVBFMMTZSS-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
102100021947 Survival motor neuron protein Human genes 0.000 description 2
101150014554 TARDBP gene Proteins 0.000 description 2
206010046298 Upper motor neurone lesion Diseases 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
238000000633 chiral stationary phase gas chromatography Methods 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
230000007937 eating Effects 0.000 description 2
238000003821 enantio-separation Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
125000003843 furanosyl group Chemical group 0.000 description 2
230000005021 gait Effects 0.000 description 2
238000010362 genome editing Methods 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
238000009593 lumbar puncture Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000020763 muscle atrophy Effects 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
208000001282 primary progressive aphasia Diseases 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
208000026473 slurred speech Diseases 0.000 description 2
241000894007 species Species 0.000 description 2
208000002320 spinal muscular atrophy Diseases 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
238000004808 supercritical fluid chromatography Methods 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 description 1
RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 1
OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 description 1
OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 1
SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
HLPXUVWTMGENBN-UHFFFAOYSA-N 3-methylidenemorpholine Chemical group C=C1COCCN1 HLPXUVWTMGENBN-UHFFFAOYSA-N 0.000 description 1
CNVRVGAACYEOQI-FDDDBJFASA-N 5,2'-O-dimethylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C(C)=C1 CNVRVGAACYEOQI-FDDDBJFASA-N 0.000 description 1
ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 1
ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
208000035657 Abasia Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
101000584986 Arabidopsis thaliana Protein phosphatase 2C 37 Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100022043 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Human genes 0.000 description 1
101710154595 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Proteins 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
CTZNINKRTKCWGU-UHFFFAOYSA-N Dinactin Natural products CC1C(=O)OC(C)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(C)CC2CCC1O2 CTZNINKRTKCWGU-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013642 Drooling Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000776160 Homo sapiens Alsin Proteins 0.000 description 1
101100191236 Homo sapiens PPM1A gene Proteins 0.000 description 1
101001010823 Homo sapiens Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000000501 Lipidoses Diseases 0.000 description 1
206010024585 Lipidosis Diseases 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010028293 Muscle contractions involuntary Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101800001065 Protein 2B Proteins 0.000 description 1
102000006831 Protein phosphatase 2C Human genes 0.000 description 1
108010047313 Protein phosphatase 2C Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
UUOCDFGUEXAVIL-UHFFFAOYSA-N Sanguinarin Natural products CNc1c(ccc2cc3OCOc3cc12)c4ccc5OCOc5c4C=O UUOCDFGUEXAVIL-UHFFFAOYSA-N 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108700026518 Sequestosome-1 Proteins 0.000 description 1
208000008630 Sialorrhea Diseases 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
208000032930 Spastic paraplegia Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000003611 TRPM7 Human genes 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
241000053227 Themus Species 0.000 description 1
108091028113 Trans-activating crRNA Proteins 0.000 description 1
102100031232 Transient receptor potential cation channel subfamily M member 7 Human genes 0.000 description 1
101710123694 Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
101710189833 Vesicle-associated membrane protein-associated protein B/C Proteins 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
HMFHBZSHGGEWLO-NEEWWZBLSA-N alpha-L-ribose Chemical compound OC[C@@H]1O[C@@H](O)[C@@H](O)[C@H]1O HMFHBZSHGGEWLO-NEEWWZBLSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000002214 arabinonucleotide Substances 0.000 description 1
RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
ZBDGIMZKOJALMU-MVWQHRGOSA-N dinactin Chemical compound C[C@@H]([C@@H]1CC[C@@H](O1)C[C@@H](OC(=O)[C@@H](C)[C@H]1CC[C@H](O1)C[C@@H](C)OC(=O)[C@@H](C)[C@@H]1CC[C@@H](O1)C[C@H](CC)OC(=O)[C@H]1C)CC)C(=O)O[C@H](C)C[C@@H]2CC[C@H]1O2 ZBDGIMZKOJALMU-MVWQHRGOSA-N 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000002641 enzyme replacement therapy Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
208000017539 frontotemporal dementia and/or amyotrophic lateral sclerosis-4 Diseases 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
235000004280 healthy diet Nutrition 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000019016 inability to swallow Diseases 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000001767 medulla oblongata Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000006996 mental state Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
URBXHNSZZLMBOT-UHFFFAOYSA-N n-[9-(4-fluoro-3,5,6-trihydroxyoxan-2-yl)purin-6-yl]benzamide Chemical compound OC1C(F)C(O)C(O)OC1N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1 URBXHNSZZLMBOT-UHFFFAOYSA-N 0.000 description 1
230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007830 nerve conduction Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
230000006780 non-homologous end joining Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
238000013439 planning Methods 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960001233 pregabalin Drugs 0.000 description 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229940084560 sanguinarine Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000779 smoke Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
239000013598 vector Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1